Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(12), P. 1714 - 1714
Published: Dec. 19, 2024
Background:
Antidepressants
such
as
SSRIs
and
SNRIs
are
widely
prescribed;
however,
significant
concerns
exist
regarding
psychiatric
adverse
drug
reactions
(ADRs),
particularly
suicidal
ideation,
suicide
attempts,
completed
suicides.
This
study
analyzes
pharmacovigilance
(PhV)
data
from
the
EudraVigilance
database
to
assess
frequency
of
ADRs,
including
suicide-related
events,
associated
with
six
commonly
used
antidepressants.
Another
aim
is
evaluate
utility
in
providing
insights
into
real-world
risks
medications,
highlighting
importance
improving
ADR
reporting
system
ensuring
completeness
reliability
reports.
Methods:
Data
December
2001
September
2024
were
analyzed
for
duloxetine,
citalopram,
escitalopram,
fluoxetine,
venlafaxine,
sertraline.
Reports
categorized
by
age,
gender,
source,
focusing
on
ADRs
suicides
attempts.
Results:
Psychiatric
accounted
a
substantial
portion
total
reported
studied
antidepressants,
ranging
33.9%
38.2%.
Venlafaxine
had
highest
count
(13,134
cases),
duloxetine
showing
relative
percentage
(38.2%).
Completed
most
frequent
venlafaxine
(1635
while
was
observed
fluoxetine
citalopram
(6%).
occurred
more
frequently
women,
(67%)
sertraline
(61.3%),
attempts
prevalent
patients
aged
18–64,
notable
incidence
0–17
age
group.
Conclusions:
highlights
patterns,
risks,
underreporting
prescribed
Using
worst-case
scenario
approach,
it
reveals
extent
gender
disparities,
impact
incomplete
risk
assessment.
General Hospital Psychiatry,
Journal Year:
2024,
Volume and Issue:
87, P. 83 - 91
Published: Feb. 7, 2024
To
investigate
the
comparative
effectiveness
of
commonly
used
selective
serotonin
reuptake
inhibitors
(SSRIs)
for
comorbid
depression
in
older
adults
with
chronic
somatic
diseases
by
applying
a
target-trial-emulation
framework.
Research Society and Development,
Journal Year:
2024,
Volume and Issue:
13(3), P. e7313345331 - e7313345331
Published: March 19, 2024
Duloxetine,
a
serotonin-norepinephrine
reuptake
inhibitor
(SNRI),
has
established
itself
as
versatile
therapeutic
agent
across
spectrum
of
psychiatric
and
neurological
disorders.
The
objective
this
article
is
to
update
the
pharmacological
properties
duloxetine.
To
end,
review
was
carried
out
on
pharmacology,
clinical
efficacy,
safety
tolerability
duloxetine,
focusing
its
application
in
treatment
major
depressive
disorder
(MDD),
generalized
anxiety
(GAD),
diabetic
peripheral
neuropathic
pain,
fibromyalgia
musculoskeletal
pain.
chronic.
Comparative
analyzes
highlight
relative
effectiveness
duloxetine
versus
other
antidepressants
unique
advantage
managing
conditions
with
overlapping
mood
pain
symptoms.
Safety
profiles
interactions,
particularly
NSAIDs
tamoxifen,
importance
personalized
plans
vigilant
monitoring.
concludes
an
assessment
utility
emphasizing
individual
patient
maximize
outcomes
while
minimizing
risks.
Future
research
directions
are
suggested
further
delineate
role
algorithms
explore
potential
new
indications.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 13, 2024
AbstractBackground:
Antidepressant
prescribing
has
increased
dramatically
worldwide
in
recent
years.
Analyzing
antidepressants
real-world
settings
can
provide
valuable
data
to
support
clinicians
and
health
policymakers.
Aim:
This
study
used
an
extensive
set
examine
the
status
trends
antidepressant
among
Chinese
Han
population
from
July
1,
2017,
June
30,
2022.
Method:
A
retrospective
was
conducted
three
hospitals.
Data
were
collected
2.5
years
before
after
onset
of
COVID-19
pandemic.
We
analyzed
number
patients
diagnosed
with
depression
corresponding
prescriptions.
To
explore
characteristics
use
across
different
ages
sexes,
stratified
analyses
performed
using
chi-square
test.
Results:
The
included
124,355
patients,
400,840
prescriptions
collected.
Fluctuating
upward
observed
drugs.
The
most
frequently
prescribed
citalopram,
escitalopram,
sertraline.
Significant
differences
by
sex
age.
pandemic
37.1%
compared
pre-pandemic
period,
rose
88.3%.
Antidepressant
monotherapy
represented
76.6%
common
combination
involved
anxiolytics.
Conclusion:
Over
past
five
years,
shown
trends.
Citalopram,
sertraline
are
currently
leading
outpatient
treatment
depressive
disorders.
significantly
affected
clinic
visits
for
depression.
International Journal of Geriatric Psychiatry,
Journal Year:
2024,
Volume and Issue:
39(11)
Published: Nov. 1, 2024
ABSTRACT
Objective
This
study
aimed
to
describe
depression
treatment
patterns,
identify
unique
trajectory
groups
using
a
group‐based
approach,
and
explore
associated
social
determinants
in
older
adults
undergoing
first‐time
during
3‐year
follow‐up.
Methods
Danish
register‐based
cohort
included
all
aged
≥
65
who
initiated
by
redeeming
antidepressant
prescriptions
(no
the
last
10
years)
between
2006
2015.
The
outcome
of
interest
2‐year
follow‐up
was
treatment,
assessed
as
redemptions
psychiatric
hospital
contacts
for
depression.
Latent
class
growth
analyses
were
applied
model
trajectories
3
years.
Multinomial
logistic
regression
used
analyze
adjusted
associations
determinates
group
membership.
Results
Among
66,540
(55.2%
females,
mean
age:
77.3
years),
we
identified
three
distinct
with
patterns
trajectories:
‘brief‐treatment’
where
individuals
stopped
within
6
months
(33.7%);
‘gradual‐withdrawal’
(26.5%)
gradually
over
2
years;
‘persistent‐treatment’
continued
entire
years
(39.8%).
Females,
single‐person
households,
residents
less‐urbanized
regions
higher
odds
membership
group,
while
age,
widowhood
or
separation,
non‐Danish
ethnicities
lower
odds.
Conclusions
Three
adults,
indicating
differential
clinical
courses
depression—potentially
influenced
determinants,
including
sex,
marital
status,
urban
residence,
ethnicity.
Early
patient
stratification
targeted
interventions
are
crucial
care
adults.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(12), P. 1714 - 1714
Published: Dec. 19, 2024
Background:
Antidepressants
such
as
SSRIs
and
SNRIs
are
widely
prescribed;
however,
significant
concerns
exist
regarding
psychiatric
adverse
drug
reactions
(ADRs),
particularly
suicidal
ideation,
suicide
attempts,
completed
suicides.
This
study
analyzes
pharmacovigilance
(PhV)
data
from
the
EudraVigilance
database
to
assess
frequency
of
ADRs,
including
suicide-related
events,
associated
with
six
commonly
used
antidepressants.
Another
aim
is
evaluate
utility
in
providing
insights
into
real-world
risks
medications,
highlighting
importance
improving
ADR
reporting
system
ensuring
completeness
reliability
reports.
Methods:
Data
December
2001
September
2024
were
analyzed
for
duloxetine,
citalopram,
escitalopram,
fluoxetine,
venlafaxine,
sertraline.
Reports
categorized
by
age,
gender,
source,
focusing
on
ADRs
suicides
attempts.
Results:
Psychiatric
accounted
a
substantial
portion
total
reported
studied
antidepressants,
ranging
33.9%
38.2%.
Venlafaxine
had
highest
count
(13,134
cases),
duloxetine
showing
relative
percentage
(38.2%).
Completed
most
frequent
venlafaxine
(1635
while
was
observed
fluoxetine
citalopram
(6%).
occurred
more
frequently
women,
(67%)
sertraline
(61.3%),
attempts
prevalent
patients
aged
18–64,
notable
incidence
0–17
age
group.
Conclusions:
highlights
patterns,
risks,
underreporting
prescribed
Using
worst-case
scenario
approach,
it
reveals
extent
gender
disparities,
impact
incomplete
risk
assessment.
